NovaBridge Biosciences ADR NBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $1.37
- Day Range
- $1.31–1.39
- 52-Week Range
- $1.31–6.79
- Bid/Ask
- $1.32 / $1.48
- Shares Outstanding
- 116.00M
- Market Cap
- $154.97M
- Volume/Avg
- 342,368 / 443,373
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 30
- Website
- https://www.novabridge.com
Valuation
|
Metric
|
NBP
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.78 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NBP
Financial Strength
|
Metric
|
NBP
|
|---|---|
Quick Ratio | 7.58 |
Current Ratio | 7.64 |
Interest Coverage | — |
Quick Ratio
NBP
Profitability
|
Metric
|
NBP
|
|---|---|
Return on Assets (Normalized) | −43.16% |
Return on Equity (Normalized) | −47.46% |
Return on Invested Capital (Normalized) | −49.50% |
Return on Assets
NBP
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|jzWg<P | LOCK|H^wL | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|cx<!!>P | LOCK|fYsBF | $76B | |||
| Moderna Inc
MRNA
| LOCK|^^!#P&? | LOCK|!> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|^^<@?s | LOCK|n? | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|SgnK<?# | LOCK|%K | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|!fVt^j | LOCK|FR!? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&Wkg<CWC | LOCK|$V@V | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|k?n<!f | LOCK|m>& | $24B | |||
| Incyte Corp
INCY
| LOCK|V&gSfV^ | LOCK|%& | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ygp<K%h | LOCK|<>T | $15B |
United States